We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Patent Office Affirms Four of Acorda’s Patents on MS Drug Ampyra Pending Court Ruling
Patent Office Affirms Four of Acorda’s Patents on MS Drug Ampyra Pending Court Ruling
The USPTO's Patent Trial and Appeal Board validated four of Acorda’s patents on the multiple sclerosis drug Ampyra, but a federal court still has to determine whether five of the drug’s patents are valid before generic drugmakers can market versions of Ampyra.